## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($169.53)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Healthcare trends: Quest Diagnostics leaders speak at major JPM event**
- Source: Stock Titan | 20251219T202149 | Neutral | Relevance: 100%
- Quest Diagnostics (NYSE: DGX) announced that its Chairman, CEO, and President, Jim Davis, along with EVP and CFO Sam Samad, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. They will discuss the company's strategy, performance, and market trends. A live webcast and an archived version will be available for investors.

**2. Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: PR Newswire | 20251219T202149 | Somewhat-Bullish | Relevance: 100%
- Quest Diagnostics announced that its Chairman, CEO, and President, Jim Davis, along with Executive Vice President and CFO, Sam Samad, will speak at the 44th Annual J.P. Morgan Healthcare Conference. They will discuss the company's strategy, performance, and market developments. The presentation will be webcast live on January 12, 2026, and an archive will be available afterward.

**3. Quest Diagnostics Inc. Stock Underperforms Thursday When Compared To Competitors**
- Source: 富途牛牛 | 20251219T140816 | Somewhat-Bearish | Relevance: 100%
- This article reports that Quest Diagnostics Inc. stock underperformed on Thursday compared to its competitors. It also mentions Unity Software's fourth-quarter financial results, noting a significant revenue increase but a quarterly loss per share.

**4. How Quest Diagnostics runs a 24/7 testing behemoth from its Tampa hub**
- Source: The Business Journals | 20251219T100732 | Bullish | Relevance: 100%
- Quest Diagnostics (NYSE: DGX) handles a significant volume of biological specimens annually, with a crucial operational hub in Temple Terrace, Florida, near the University of South Florida. The company is actively investing in AI and automation to enhance its testing capabilities and efficiency at this facility, which operates 24/7. This strategic expansion underscores Quest Diagnostics' commitment to leveraging advanced technology in its diagnostic services.

**5. Aaron Wealth Advisors LLC Makes New Investment in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251217T082317 | Somewhat-Bullish | Relevance: 98%
- Aaron Wealth Advisors LLC has initiated a new investment in Quest Diagnostics (DGX), acquiring 7,618 shares valued at approximately $1.45 million. This comes as institutional investors now hold about 88.06% of the stock, despite recent significant insider selling, including the CEO reducing his stake by over 31%. Quest Diagnostics reported strong Q3 earnings, exceeding analyst estimates, and announced a quarterly dividend, with analysts maintaining a "Moderate Buy" consensus rating for the company.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-5.2% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $8.9M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 17.0x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 17.0 |
| Current P/E | 17.9 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.9% to -2.3% (-5.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. MACD histogram bearish (-0.88), momentum weakening. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.31% (CS: 19) | Weak |
| RSI_14 | 36.6 | Neutral |
| MACD Histogram | -0.88 | Bearish |
| vs SMA20 | 0.960x | Below |
| vs SMA50 | 0.961x | Below |
| vs SMA200 | 0.994x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $176.03
- **Stop Loss:** $169.53 (3.7% risk)
- **Target:** $182.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 184
- **Position Value:** $32,389.52
- **Portfolio %:** 32.39%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*